Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SlabON-BMSC is a preclinical-stage cell therapy candidate developed by Akrocell Biosciences for the purpose of bone regeneration. The product utilizes the company's proprietary SlabON® platform, which is categorized as an advanced biopharmaceutical technology designed to provide a supportive environment for tissue repair. This specific therapy incorporates bone marrow-derived mesenchymal stem cells (BMSCs), also known as bone marrow stromal cells, which are integrated with the SlabON® scaffold. The mechanism involves leveraging the regenerative potential of mesenchymal stem cells to promote osteogenesis and structural restoration of bone tissue. It is currently positioned in the preclinical phase of development within the Akrocell pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SlabON-BMSC.